Neoadjuvant chemo is well tolerated in high-risk PCa
September 1st 2006Atlanta-Neoadjuvant docetaxel added to androgen suppression therapy and radiation therapy appears to be safe and active in patients with high-risk localized prostate cancer, according to findings of a new phase II study from Canada reported here at the American Society of Clinical Oncology annual meeting.
RALP may offer improved margins, ease of transition
September 1st 2006Atlanta-Positive surgical margin rates decrease as experience with robot-assisted laparoscopic prostatectomy (RALP) increases. In addition, formal laparoscopic training may not be necessary for optimizing some outcomes with the robotic procedure, according to the findings of two new studies presented here at the AUA annual meeting.
Botulinum toxin shown to improve detrusor overactivity
May 1st 2003Madrid, Spain-Botulinum-A toxin shows positive results as an alternativetreatment of neurogenic detrusor overactivity when oral therapies or intravesicalanticholinergics fail or are intolerable, according to results of four separatestudies presented at the European Association of Urology 18th congress here.The agent, although FDA-approved for the treatment of skin wrinkles andrelated indications, is not approved for detrusor overactivity but has beenused by some U.S. and European urologists for this indication.
Lifestyle changes may prevent, reverse PCa
May 1st 2003Chicago-Leading a healthy lifestyle may stop or even reverse the progression of prostate cancer as measured by PSA levels in men undergoing watchful waiting, according to the findings of the first randomized, controlled clinical trial on the subject.